Siemens Healthineers stock faces investor roadshows after FY2026

Siemens Healthineers will meet investors at a series of European capital-market events on Tuesday, November 10, 2026. The company's investor-relations calendar lists a UBS roadshow in Frankfurt, a J.P. Morgan roadshow in Paris and the UBS European Healthcare Conference in London.

What Investors Will Be Watching

The meetings follow a strong close to fiscal 2026. In its fiscal 2026 results release, Siemens Healthineers reported comparable revenue growth of 4.0%, an adjusted EBIT margin of 16.2% and adjusted basic earnings per share of 2.42 euros. Free cash flow reached 2.4 billion euros, and the company proposed an unchanged dividend of 1.00 euro per share.

Management's framework for fiscal 2027 points to comparable revenue growth of 4.0% to 5.0% and adjusted basic earnings per share of 2.20 to 2.40 euros. That combination leaves execution and margin development central to the investor discussion as the company moves beyond the latest annual figures.

Diagnostics Remains Key Test

The fourth quarter showed a clear split between business lines. Imaging generated comparable revenue growth of 10.0% and an adjusted EBIT margin of 21.9%, while Diagnostics recorded a comparable revenue decline of 4.2% and an adjusted EBIT margin of 5.4%. Precision Therapy delivered comparable growth of 4.8% and an adjusted EBIT margin of 13.8%.

The company is also initiating the carve-out of its Diagnostics business, which is to be renamed Olyrian Diagnostics. At group level, the future brand is planned to become Healthineers, with the transition scheduled to begin in 2027.

The real-time quote of Siemens Healthineers stock traded at 44.51 euros on Lang & Schwarz at 18:06 CET on Sunday, November 8, 2026.

Investors can follow the broader German market through the DAX.

Further developments can be found in more news and analyses on Siemens Healthineers stock.